Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1996 Oct;70(10):7171–7181. doi: 10.1128/jvi.70.10.7171-7181.1996

Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.

G Tachedjian 1, J Mellors 1, H Bazmi 1, C Birch 1, J Mills 1
PMCID: PMC190770  PMID: 8794364

Abstract

Both foscarnet (PFA) and zidovudine (AZT) select for drug-resistant variants of human immunodeficiency virus type 1 (HIV-1), but the interactions between the mutations causing such resistance are unknown. The introduction of the previously identified PFA resistance mutation W to G at codon 88 (W88G), E89K, L92I, or Q161L into an HIV-1 strain having the four known AZT resistance mutations completely reversed high-level AZT resistance. Two additional PFA resistance mutations, W88S and S156A, partially suppressed AZT resistance. Phenotypic reversion of AZT resistance by W88S, W88G, E89K, L921, and S156A was associated with a concomitant suppression of PFA resistance. The degree to which PFA resistance mutations reversed AZT resistance was directly correlated with each mutation's ability to confer high-level PFA resistance (> or = 5.0-fold) and AZT hypersusceptibility in a wild-type genetic background. Highly PFA-resistant HIV- 1 strains were hypersusceptible to AZT; conversely, AZT-resistant strains with M41L and T215Y; M41L, L210W, and T215Y; or M41L, D67N, K70R, and T215Y mutations were 2.2- to 2.5-fold hypersusceptible to PFA. Prolonged in vitro selection of wild-type or AZT-resistant HIV-1 strains with the combination AZT and PFA failed to generate coresistant virus, indicating that dual resistance was relatively difficult to achieve. Strains selected by passage in PFA plus AZT were phenotypically PFA resistant and AZT susceptible despite multiple reverse transcriptase mutations known to confer AZT resistance. These data show that PFA resistance mutations can phenotypically reverse AZT resistance and that AZT and PFA resistance might be mutually exclusive. The reciprocal interactions between AZT and PFA resistance-conferring mutations have implications for structure-function studies of the HIV-1 reverse transcriptase.

Full Text

The Full Text of this article is available as a PDF (272.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes W. M. PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2216–2220. doi: 10.1073/pnas.91.6.2216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Birch C. J., Tachedjian G., Doherty R. R., Hayes K., Gust I. D. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis. 1990 Sep;162(3):731–734. doi: 10.1093/infdis/162.3.731. [DOI] [PubMed] [Google Scholar]
  3. Cheeseman S. H., Havlir D., McLaughlin M. M., Greenough T. C., Sullivan J. L., Hall D., Hattox S. E., Spector S. A., Stein D. S., Myers M. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):141–151. [PubMed] [Google Scholar]
  4. Coffin J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483–489. doi: 10.1126/science.7824947. [DOI] [PubMed] [Google Scholar]
  5. Collier A. C., Coombs R. W., Fischl M. A., Skolnik P. R., Northfelt D., Boutin P., Hooper C. J., Kaplan L. D., Volberding P. A., Davis L. G. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993 Oct 15;119(8):786–793. doi: 10.7326/0003-4819-119-8-199310150-00003. [DOI] [PubMed] [Google Scholar]
  6. Crumpacker C. S. Mechanism of action of foscarnet against viral polymerases. Am J Med. 1992 Feb 14;92(2A):3S–7S. doi: 10.1016/0002-9343(92)90329-a. [DOI] [PubMed] [Google Scholar]
  7. D'Aquila R. T., Johnson V. A., Welles S. L., Japour A. J., Kuritzkes D. R., DeGruttola V., Reichelderfer P. S., Coombs R. W., Crumpacker C. S., Kahn J. O. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med. 1995 Mar 15;122(6):401–408. doi: 10.7326/0003-4819-122-6-199503150-00001. [DOI] [PubMed] [Google Scholar]
  8. Eriksson B. F., Schinazi R. F. Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1989 May;33(5):663–669. doi: 10.1128/aac.33.5.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Erlich K. S., Jacobson M. A., Koehler J. E., Follansbee S. E., Drennan D. P., Gooze L., Safrin S., Mills J. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann Intern Med. 1989 May 1;110(9):710–713. doi: 10.7326/0003-4819-110-9-710. [DOI] [PubMed] [Google Scholar]
  10. Grob P. M., Wu J. C., Cohen K. A., Ingraham R. H., Shih C. K., Hargrave K. D., McTague T. L., Merluzzi V. J. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res Hum Retroviruses. 1992 Feb;8(2):145–152. doi: 10.1089/aid.1992.8.145. [DOI] [PubMed] [Google Scholar]
  11. Gurusinghe A. D., Land S. A., Birch C., McGavin C., Hooker D. J., Tachedjian G., Doherty R., Deacon N. J. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J Med Virol. 1995 Jul;46(3):238–243. doi: 10.1002/jmv.1890460312. [DOI] [PubMed] [Google Scholar]
  12. Harada S., Koyanagi Y., Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science. 1985 Aug 9;229(4713):563–566. doi: 10.1126/science.2992081. [DOI] [PubMed] [Google Scholar]
  13. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  14. Jacobo-Molina A., Ding J., Nanni R. G., Clark A. D., Jr, Lu X., Tantillo C., Williams R. L., Kamer G., Ferris A. L., Clark P. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6320–6324. doi: 10.1073/pnas.90.13.6320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jacobson M. A., Crowe S., Levy J., Aweeka F., Gambertoglio J., McManus N., Mills J. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis. 1988 Oct;158(4):862–865. [PubMed] [Google Scholar]
  16. Japour A. J., Welles S., D'Aquila R. T., Johnson V. A., Richman D. D., Coombs R. W., Reichelderfer P. S., Kahn J. O., Crumpacker C. S., Kuritzkes D. R. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J Infect Dis. 1995 May;171(5):1172–1179. doi: 10.1093/infdis/171.5.1172. [DOI] [PubMed] [Google Scholar]
  17. Kaiser L., Perrin L., Hirschel B., Furrer H., Von Overbeck J., Olmari M., Yerly S. Foscarnet decreases human immunodeficiency virus RNA. J Infect Dis. 1995 Jul;172(1):225–227. doi: 10.1093/infdis/172.1.225. [DOI] [PubMed] [Google Scholar]
  18. Katzenstein D. A. Viral phenotype and genotype as markers in clinical trials. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 (Suppl 2):S25–S34. [PubMed] [Google Scholar]
  19. Kellam P., Boucher C. A., Larder B. A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1934–1938. doi: 10.1073/pnas.89.5.1934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kellam P., Boucher C. A., Tijnagel J. M., Larder B. A. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol. 1994 Feb;75(Pt 2):341–351. doi: 10.1099/0022-1317-75-2-341. [DOI] [PubMed] [Google Scholar]
  21. Kellam P., Larder B. A. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol. 1995 Feb;69(2):669–674. doi: 10.1128/jvi.69.2.669-674.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Koshida R., Vrang L., Gilljam G., Harmenberg J., Oberg B., Wahren B. Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet. Antimicrob Agents Chemother. 1989 May;33(5):778–780. doi: 10.1128/aac.33.5.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kozal M. J., Shafer R. W., Winters M. A., Katzenstein D. A., Merigan T. C. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis. 1993 Mar;167(3):526–532. doi: 10.1093/infdis/167.3.526. [DOI] [PubMed] [Google Scholar]
  24. Larder B. A. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1992 Dec;36(12):2664–2669. doi: 10.1128/aac.36.12.2664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  26. Larder B. A., Kellam P., Kemp S. D. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS. 1991 Feb;5(2):137–144. doi: 10.1097/00002030-199102000-00002. [DOI] [PubMed] [Google Scholar]
  27. Larder B. A., Kemp S. D., Harrigan P. R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995 Aug 4;269(5224):696–699. doi: 10.1126/science.7542804. [DOI] [PubMed] [Google Scholar]
  28. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  29. Larder B. A., Kemp S. D., Purifoy D. J. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci U S A. 1989 Jul;86(13):4803–4807. doi: 10.1073/pnas.86.13.4803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Larder B. A., Purifoy D. J., Powell K. L., Darby G. Site-specific mutagenesis of AIDS virus reverse transcriptase. 1987 Jun 25-Jul 1Nature. 327(6124):716–717. doi: 10.1038/327716a0. [DOI] [PubMed] [Google Scholar]
  31. Mellors J. W., Bazmi H. Z., Schinazi R. F., Roy B. M., Hsiou Y., Arnold E., Weir J., Mayers D. L. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother. 1995 May;39(5):1087–1092. doi: 10.1128/aac.39.5.1087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Montaner J. S., Singer J., Schechter M. T., Raboud J. M., Tsoukas C., O'Shaughnessy M., Ruedy J., Nagai K., Salomon H., Spira B. Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS. 1993 Feb;7(2):189–196. doi: 10.1097/00002030-199302000-00006. [DOI] [PubMed] [Google Scholar]
  33. Neate E. V., Pringle R. C., Jowett J. B., Healey D. S., Gust I. D. Isolation of HIV from Australian patients with AIDS, AIDS related conditions and healthy antibody positive individuals. Aust N Z J Med. 1987 Oct;17(5):461–466. doi: 10.1111/j.1445-5994.1987.tb00096.x. [DOI] [PubMed] [Google Scholar]
  34. Nguyen M. H., Schinazi R. F., Shi C., Goudgaon N. M., McKenna P. M., Mellors J. W. Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines. Antimicrob Agents Chemother. 1994 Oct;38(10):2409–2414. doi: 10.1128/aac.38.10.2409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther. 1989;40(2):213–285. doi: 10.1016/0163-7258(89)90097-1. [DOI] [PubMed] [Google Scholar]
  36. Ragni M. V., Amato D. A., LoFaro M. L., DeGruttola V., Van Der Horst C., Eyster M. E., Kessler C. M., Gjerset G. F., Ho M., Parenti D. M. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups. Blood. 1995 May 1;85(9):2337–2346. [PubMed] [Google Scholar]
  37. Richman D. D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S. A., Sullivan J., Cheeseman S., Barringer K., Pauletti D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994 Mar;68(3):1660–1666. doi: 10.1128/jvi.68.3.1660-1666.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Rocancourt D., Bonnerot C., Jouin H., Emerman M., Nicolas J. F. Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J Virol. 1990 Jun;64(6):2660–2668. doi: 10.1128/jvi.64.6.2660-2668.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Safrin S., Berger T. G., Gilson I., Wolfe P. R., Wofsy C. B., Mills J., Biron K. K. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991 Jul 1;115(1):19–21. doi: 10.7326/0003-4819-115-1-19. [DOI] [PubMed] [Google Scholar]
  40. Safrin S., Crumpacker C., Chatis P., Davis R., Hafner R., Rush J., Kessler H. A., Landry B., Mills J. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1991 Aug 22;325(8):551–555. doi: 10.1056/NEJM199108223250805. [DOI] [PubMed] [Google Scholar]
  41. Sandstrom E. G., Kaplan J. C., Byington R. E., Hirsch M. S. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet. 1985 Jun 29;1(8444):1480–1482. doi: 10.1016/s0140-6736(85)92255-x. [DOI] [PubMed] [Google Scholar]
  42. Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis P., Danner S. A., Mulder J., Loveday C., Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995 Jun;171(6):1411–1419. doi: 10.1093/infdis/171.6.1411. [DOI] [PubMed] [Google Scholar]
  43. Shafer R. W., Iversen A. K., Winters M. A., Aguiniga E., Katzenstein D. A., Merigan T. C. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis. 1995 Jul;172(1):70–78. doi: 10.1093/infdis/172.1.70. [DOI] [PubMed] [Google Scholar]
  44. Shafer R. W., Kozal M. J., Winters M. A., Iversen A. K., Katzenstein D. A., Ragni M. V., Meyer W. A., 3rd, Gupta P., Rasheed S., Coombs R. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994 Apr;169(4):722–729. doi: 10.1093/infdis/169.4.722. [DOI] [PubMed] [Google Scholar]
  45. Shirasaka T., Kavlick M. F., Ueno T., Gao W. Y., Kojima E., Alcaide M. L., Chokekijchai S., Roy B. M., Arnold E., Yarchoan R. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2398–2402. doi: 10.1073/pnas.92.6.2398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. St Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991 Sep 27;253(5027):1557–1559. doi: 10.1126/science.1716788. [DOI] [PubMed] [Google Scholar]
  47. Starnes M. C., Cheng Y. C. Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate. Virus Genes. 1989 May;2(3):241–251. doi: 10.1007/BF00125341. [DOI] [PubMed] [Google Scholar]
  48. Tachedjian G., Hooker D. J., Gurusinghe A. D., Bazmi H., Deacon N. J., Mellors J., Birch C., Mills J. Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology. 1995 Sep 10;212(1):58–68. doi: 10.1006/viro.1995.1453. [DOI] [PubMed] [Google Scholar]
  49. Tachedjian G., Hoy J., McGavin K., Birch C. Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient. J Med Virol. 1994 Feb;42(2):207–211. doi: 10.1002/jmv.1890420220. [DOI] [PubMed] [Google Scholar]
  50. Tachedjian M., Krywult J., Moore R. J., Hodgson A. L. Caseous lymphadenitis vaccine development: site-specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene. Vaccine. 1995 Dec;13(18):1785–1792. doi: 10.1016/0264-410x(95)00144-p. [DOI] [PubMed] [Google Scholar]
  51. Tantillo C., Ding J., Jacobo-Molina A., Nanni R. G., Boyer P. L., Hughes S. H., Pauwels R., Andries K., Janssen P. A., Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol. 1994 Oct 28;243(3):369–387. doi: 10.1006/jmbi.1994.1665. [DOI] [PubMed] [Google Scholar]
  52. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653–5656. doi: 10.1073/pnas.90.12.5653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Tudor-Williams G., St Clair M. H., McKinney R. E., Maha M., Walter E., Santacroce S., Mintz M., O'Donnell K., Rudoll T., Vavro C. L. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet. 1992 Jan 4;339(8784):15–19. doi: 10.1016/0140-6736(92)90140-x. [DOI] [PubMed] [Google Scholar]
  54. Vrang L., Oberg B. PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase. Antimicrob Agents Chemother. 1986 May;29(5):867–872. doi: 10.1128/aac.29.5.867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES